MAP2K7 and eosinophilia-myalgia syndrome: Mainly, preventing the activation of NF-κB and blocking the nuclear transduction effect of NF-κB have a therapeutic effect on EMs, but have no obvious effect on the expression levels of the upstream genes MEK and ERK.